Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Over 2 years have passed since the start of the COVID-19 pandemic, which has claimed
millions of lives. Unlike the early days of the pandemic, when management decisions were …

Background Respiratory syncytial virus (RSV) is widely known as a frequent cause of
respiratory distress among adults, particularly older people. Recent years have witnessed …

The progress in human disease treatment can be greatly advanced through the
implementation of nanomedicine. This approach involves targeted and cell-specific therapy …

Introduction Nirsevimab is an extended half-life (M252Y/S254T/T256E [YTE]-modified)
monoclonal antibody to the pre-fusion conformation of the respiratory syncytial virus (RSV) …

Real-time monitoring of biopharmaceutical reactors is becoming increasingly important as
the processes become more complex. During the continuous manufacturing of monoclonal …

The nasal mucosa is an important initial site of host defense against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) infection. However, intramuscularly administered …

Background Respiratory syncytial virus (RSV) is the leading global cause of respiratory
infections and is responsible for about 3 million hospitalizations and more than 100,000 …

Highlights•mAbs mixture targeting independent epitopes are better therapeutics.•Optimizing
antibody efficacy: in vitro maturation, afucosylation, Fc modifications.•Monitoring of natural …

Antibody engineering has developed into a wide-reaching field, impacting a multitude of
industries, most notably healthcare and diagnostics. The seminal work on developing the …